Clik here to view.
Biogen Idec and Samsung Bioepis Announce Agreement to Market Anti-TNF...
CAMBRIDGE, Mass. & SEOUL, Korea Biogen Idec (NASDAQ: BIIB) and Samsung Bioepis today announced that through their joint venture, Biogen Idec has exercised its right to enter into an agreement to...
View ArticleClik here to view.
Major Korean Company Purchases Spire’s Advanced Simulator and EL Test...
BEDFORD, Mass. Spire Corporation (OTCQB: SPIR), a global solar company providing capital equipment and turn-key manufacturing lines to produce photovoltaic (“PV”) modules and optoelectronics thin...
View ArticleClik here to view.
Innate Immunotherapeutics Completes $10M IPO
SYDNEY Innate Immunotherapeutics is pleased to announce it has successfully raised A$10 million through its Initial Public Offer (IPO) and will immediately commence planning its clinical trial for...
View ArticleClik here to view.
Cegedim Relationship Management最新调查：61%的生命科学企业高管认为“不断变化的商业业务模式”是最大痛点
巴黎 (美国商业资讯)–Cegedim Relationship Management今日发布标题为 《2013全球生命科学行业洞察》的最新思想领袖报告。报告对就行业痛点、通过创新实现增长以及解决办法向全球生命科学企业决策者展开的调查结果进行了分析。 主要变化：行业挑战、业务模式和创新趋势变化...
View ArticleClik here to view.
Roche and Genentech Acquire Unlimited Access to Open Monoclonal Technology’s...
PALO ALTO, Calif. Open Monoclonal Technology, Inc. (OMT), an innovator in transgenic research for discovery of human therapeutic antibodies, today announced that Genentech, a member of the Roche...
View ArticleClik here to view.
pSivida Corp. Reports FDA Labeling Discussions for ILUVIEN® for DME; Advisory...
WATERTOWN, Mass. pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that its licensee...
View ArticleClik here to view.
Blaze Bioscience Announces Initiation of First-in-Human Phase 1 Clinical...
SEATTLE & MELBOURNE, Australia Blaze Bioscience, Inc. and its subsidiary, Blaze Bioscience Australia Pty Ltd, today announced the initiation of the first Phase 1 clinical study of the first...
View ArticleClik here to view.
United Health Products Inc. Receives Initial HemoStyp® Order for Australian...
WESTBURY, N.Y. United Health Products, Inc. (OTCQB:UEEC) announced that its Australian distributor, Critical Health Products Ltd., has placed an initial order for HemoStyp® gauze products. The order...
View ArticleClik here to view.
Octapharma公司的II/III期复发性多发性硬化症靶向治疗试验入组首例患者
瑞士LACHEN (美国商业资讯)–世界上最大的全球性人类蛋白质制造商之一Octapharma AG今天宣布，该公司的GAM-27 II/III期复发性多发性硬化症(RMS)治疗临床试验已入组最先的2例患者。该研究旨在通过免疫球蛋白(Octagam 5%)静脉给药，在不适用一线药物的患者中寻求较低的年化复发率这一总体临床收益。...
View ArticleClik here to view.
Clik here to view.
ERYTECH Announces the Decision of USPTO to Extend the Additional Exclusivity...
LYON, France Regulatory News: ERYTECH (NYSE Euronext Paris: FR0011471135 – ERYP), a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology...
View ArticleClik here to view.
PeptiDream Announces Collaboration and License Agreement with Lilly to...
TOKYO PeptiDream Inc, a Tokyo-based biopharmaceutical company (PeptiDream)(TOKYO:4587), announced that they have entered into a Collaboration and License Agreement with US-based Eli Lilly and...
View ArticleClik here to view.
オクタファルマが再発性多発性硬化症の標的治療を検討する第2/3相試験で初の患者組み入れ
スイス・ラッヘン （ビジネスワイヤ） — ヒトタンパク質製品メーカーとして世界最大手のオクタファルマは本日、再発性多発性硬化症（RMS）治療のGAM-27第2/3相臨床試験に患者2人を初めて組み入れたと発表しました。試験では第一選択療法が適さない患者に対し、免疫グロブリン（オクタガム5%）の静脈内投与により、年間再発率の低下という総合的な臨床ベネフィットを支援できるかについて検討します。...
View ArticleClik here to view.
エリテック、中核プロセス特許の独占期間をほぼ4年延長するというUSPTOの決定を発表
仏リヨン （ビジネスワイヤ） — 急性白血病および医療ニーズが満たされていないその他の腫瘍適応症を対象に革新的治療薬の開発に当たっているフランスのバイオ製薬企業エリテック(NYSE Euronext Paris: FR0011471135 – ERYP）は、当社の中核プロセスの米国特許が2年からほぼ4年へと独占期間を延長して交付されるという最終許可通知を受領したことを発表します。...
View ArticleClik here to view.
DxTerity’s REDI-Dx Wins 2013 NCT CBRNe Product of the Year Award
LOS ANGELES DxTerity Diagnostics announced that REDI-Dx™, the company’s blood-based gene expression test for estimating individualized levels of radiation exposure,* was named the 2013 NCT CBRNe...
View ArticleClik here to view.
CARMAT的生物假体人工心脏首次植入人体
巴黎 (美国商业资讯) –CARMAT (Paris:ALCAR) (FR0010907956, ALCAR)是世界上最先进的全人工心脏课题的设计者和开发者, 为罹患终末期心力衰竭的人士提供另一种医疗选择。该公司宣布，依据ANSM（法国卫生部国家药品及保健产品安全署）和个人保护委员会（伦理委员会）颁发的批复，公司的人工心脏已在一项可行性研究中首次植入人体。...
View ArticleClik here to view.
Menicon, Azabu University, and Yokohama City University Identify the Glaucoma...
NAGOYA, Japan Menicon announces that an article entitled, “Dogs and humans share a common susceptibility gene SRBD1 for glaucoma risk”, which presents the results of a study conducted by Menicon,...
View ArticleClik here to view.
カルマトのバイオプロテーゼ人工心臓を初めてヒトに移植
パリ （ビジネスワイヤ） — 世界最先端の完全人工心臓プロジェクトを設計・開発し、末期心不全を患う人々に代替法を提供しているカルマト（Paris:ALCAR）（FR0010907956,...
View ArticleClik here to view.
Menicon、麻布大学和横滨市立大学发现犬类青光眼易感基因SRBD1
日本名古屋 (美国商业资讯)–Menicon宣布，一篇题为“犬类的青光眼风险易感基因SRBD1与人类相同”的论文已发表于科学期刊PLoS ONE，该论文呈报了Menicon、麻布大学和横滨市立大学开展的一项研究（以下称“该研究”）的结果。 Menicon与麻布大学和横滨市立大学合作开展的研究发现，日本柴犬的青光眼易感基因与人类相同。...
View Article